Biohaven (BHVN) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Biohaven (BHVN) over the past year, gaining 30.6% versus a loss of 22.2%. Trevi Therapeutics is the larger company by market cap ($1.87 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | TRVI |
|---|---|---|
| Share price | $12.14 | $13.09 |
| Market cap | $1.83B | $1.87B |
| 1-day change | +1.76% | +2.07% |
| YTD return | +5.67% | +2.44% |
| 1-year return | -22.23% | +30.60% |
| 5-year return | — | +894.19% |
| EPS (TTM) | $-4.56 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | $-42.76M |
| 52-week high | $18.57 | $20.22 |
| 52-week low | $7.48 | $9.28 |
| Distance from 52-week high | -34.61% | -35.26% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +75.21% | +115.28% |
| Average volume | 2.62M | 2.03M |
| Shares outstanding | 151.04M | 142.48M |
| Employees | 274 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed BHVN by 52.8 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
BHVN vs TRVI FAQ
Which is bigger, Biohaven or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.87B compared with $1.83B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or TRVI?
TRVI returned +30.60% over the past 12 months, compared with -22.23% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.